{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:11:29Z","timestamp":1791659489453,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Chemical Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.annonc.2026.02.015","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:47:57Z","timestamp":1772473677000},"page":"849-860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Trastuzumab deruxtecan in hormone receptor-positive, HER2-low\/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4\/6 inhibitor and baseline burden of disease"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-7602","authenticated-orcid":false,"given":"R.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-667X","authenticated-orcid":false,"given":"C.H.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"F.","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7224","authenticated-orcid":false,"given":"K.H.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Bagegni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Collignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-2718","authenticated-orcid":false,"given":"M.","family":"Gil-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Andrzejuk-\u0106wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schwaederle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"35","key":"10.1016\/j.annonc.2026.02.015_bib1","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.02.015_bib2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer\u2013capivasertib-fulvestrant: ASCO rapid recommendation update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.02.015_bib3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.02.015_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-023-00520-7","article-title":"The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"9","author":"Grinshpun","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"28","key":"10.1016\/j.annonc.2026.02.015_bib5","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized Phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2026.02.015_bib6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.02.015_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103691","article-title":"Real-world treatment patterns and outcomes in patients with HR+\/HER2\u2212 metastatic breast cancer treated with chemotherapy in the United States","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.annonc.2026.02.015_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.02.015_bib9","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.2147\/CMAR.S300869","article-title":"Prognostic factors in hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2\u2212) advanced breast cancer: a systematic literature review","volume":"13","author":"Cuy\u00fan Carter","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"8","key":"10.1016\/j.annonc.2026.02.015_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2026.02.015_bib11","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2026.02.015_bib12","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.annonc.2026.02.015_bib13","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.annonc.2026.02.015_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"12","key":"10.1016\/j.annonc.2026.02.015_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.02.015_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2026.02.015_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101931","volume":"59","author":"Lambertini","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.annonc.2026.02.015_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.02.015_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.02.015_bib24","article-title":"DESTINY-Breast06 (DB-06) post-hoc analysis by physician\u2019s choice of chemotherapy (TPC): efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor\u2013positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)","volume":"10","author":"Barrios","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.annonc.2026.02.015_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105082","article-title":"Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial","volume":"10","author":"Hu","year":"2025","journal-title":"ESMO Open"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.02.015_bib26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.2025.43.16_suppl.1013","article-title":"Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in HER2-low\/ultralow, hormone receptor\u2013positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)","volume":"43","author":"Dent","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.02.015_bib27","series-title":"Trastuzumab deruxtecan vs treatment of physician\u2019s choice in patients with HER2-low unresectable and\/or metastatic breast cancer: subgroup analyses from DESTINY-Breast04 (Abstract P1-11-01)","author":"Harbeck","year":"2022"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:22:21Z","timestamp":1779135741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0923753426000712"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.02.015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab deruxtecan in hormone receptor-positive, HER2-low\/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4\/6 inhibitor and baseline burden of disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}